Please login to the form below

Not currently logged in
Email:
Password:

Biogen's Douglas Williams departs for biotech start-up

Research head will be first member of a new cancer-focused firm

Biogen Douglas WilliamsDouglas Williams will this week leave Biogen for a new role as CEO of an as-yet unnamed biotech start-up that will focus on cancer diagnostics and therapies.

Williams had led Biogen's R&D  since 2011 as executive vice president of research and development, prior to which his industry roles included a six year stint at Seattle-based biotech Zymogenetics (now part of BMS), where he rose to be its CEO.

He said: “While I am sad to leave Biogen I am excited about the opportunity to follow a real passion of mine. I am proud of the progress of the company's R&D organisation and am pleased that it will be in very capable hands.”

Williams will be replaced by chief medical officer Alfred Sandrock and chief scientific officer Spyros Artavanis-Tsakonas, who will be handed joint responsibility for Biogen Research and Development.

Biogen's CEO George Scangos said: “All of us at Biogen appreciate Doug's contributions to the rapid development of our Research and Development organisation.

“We are fortunate to have Al Sandrock and Spyros Artavanis-Tsakonas to lead the work to which Biogen is dedicated.”

27th July 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics